On this page:OverviewPublicationsResearchersInstitutionsOpen access
ScholarIQanswers from OpenAlex

UK Research and Innovation

InstitutionResearch output, impact & collaborations

UK Research and Innovation is a institution indexed in ScholarIQ from OpenAlex.

What is known about UK Research and Innovation?

ScholarIQrecord summary

UK Research and Innovation is a research organisation in Swindon, GB. OpenAlex records 1,424 works and 282,292 citations for it. 296 researchers list it as their most recent affiliation.

How many works does UK Research and Innovation have?

ScholarIQindexed works

UK Research and Innovation has 1,424 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does UK Research and Innovation have?

ScholarIQcitation count

UK Research and Innovation has 282,292 citations in the OpenAlex counts ScholarIQ stores.

How many researchers are at UK Research and Innovation?

ScholarIQresearcher count

UK Research and Innovation has 296 researchers in the ScholarIQ index.

What is the average h-index at UK Research and Innovation?

ScholarIQavg h-index

UK Research and Innovation has an average h-index of 54 in OpenAlex.

What is the ROR of UK Research and Innovation?

ScholarIQror

The ROR for UK Research and Innovation is on the source record.

What is the OpenAlex record for UK Research and Innovation?

ScholarIQopenalex

The OpenAlex for UK Research and Innovation is on the source record.

Who are the most-cited researchers behind UK Research and Innovation?

ScholarIQtop researchers by citations
1
Andrew Wardley · Breast Cancer Treatment Studies
324 works20,142 citations

What are the most-cited papers on UK Research and Innovation?

ScholarIQmost cited works
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith, Marion Procter, Richard D. Gelber, Sébastien Guillaume, A. Feyereislova, Mitch Dowsett, Aron Goldhirsch, Michael Untch, Gabriella Mariani, José Baselga, Manfred Kaufmann, David Cameron, Richard H. Bell, Jonas Bergh, Robert L. Coleman, Andrew Wardley, Nadia Harbeck, R.I. Lopez, Peter Mallmann, Karen A. Gelmon, Nicholas Wilcken, Erik Wist, Pedro Sánchez‐Rovira, Martine Piccart
The Lancet. 20071,514 Citations
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Andrew Tutt, Holly Tovey, Maggie C.U. Cheang, Sarah Kernaghan, Lucy Kilburn, Patrycja Gazińska, Julie Owen, Jacinta Abraham, Sophie Barrett, Peter Barrett‐Lee, Robert Brown, Stephen Chan, Mitch Dowsett, James M. Flanagan, Lisa Fox, Anita Grigoriadis, Alexander Gutin, Catherine Harper‐Wynne, M. Hatton, Katherine A. Hoadley, Jyoti Parikh, Peter J. Parker, Charles M. Perou, Rebecca Roylance, Vandna Shah, Adam Shaw, Ian E. Smith, Kirsten M. Timms, Andrew Wardley, G. Wilson, Cheryl Gillett, Jerry S. Lanchbury, Alan Ashworth, Nazneen Rahman, Mark Harries, Paul Ellis, Sarah E. Pinder, Judith M. Bliss
Nature Medicine. 2018911 CitationsOPEN ACCESS
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
David Miles, Joseph Gligorov, Fabrice André, David Cameron, Andreas Schneeweiß, Carlos H. Barrios, Binghe Xu, Andrew Wardley, Diego Kaen, Livia Andrade, Semiglazov Vf, Mattea Reinisch, Shilpen Patel, Monika Patre, L. Morales, Sipahee Lal Patel, Manika Kaul, Teresa Barata, Joyce O’Shaughnessy, Q. Zhang, Binghe Xu, Zhimin Shao, Xiangyu Wang, Cuizhi Geng, Xingchen Yan, Zhongsheng Tong, Kunwei Shen, Yongmei Yin, Tao Sun, James Chih‐Hsin Yang, J Feng, Min Yan, Yan Wang, Qiang Liu, S. Zhang, Michelino De Laurentiis, Armando Santoro, Valentina Guarneri, Marco Colleoni, Clara Natoli, Laura Cortesi, Sabino De Placido, Lorenzo Gianni, Francesco Ferraù, Lorenzo Livi, Alberto Zambelli, Lucia Del Mastro, Giuseppe Tonini, Filippo Montemurro, Giulia Bianchi, R. Pedersini, Salvatore A. Del Prete, Giacomo Allegrini, Giuseppe Naso, Patrizia Vici, D. Loirat, Audrey Mailliez, Franck Priou, Olivier Trédan, F. Dalenc, Christophe Perrin, Joseph Gligorov, Morales-Pancorbo David, Nadine Dohollou, Luís Teixeira, Fabien Brocard, Antoine Arnaud, Suzette Delaloge, Jean‐Philippe Spano, Luigi Mansi, Livia Andrade, Fernanda Damian, José Luiz Pedrini, Sandra M. Aleixo, Roberto Hegg, R. Junior, Mattea Reinisch, Marcus Schmidt, C. Wenzel, E.‐M. Grischke, Andreas Schneeweiß, Marianne Just, Nadia Harbeck, Claudia Schumacher, Ubong Peters, Dorothea Fischer, Helmut Forstbauer, Rüdiger Liersch, Ellen Warner, Nathaniel Bouganim, C. T. Doyle, Julie Price Hiller, Ted Vandenberg, Michel Pavic, Andrew Robinson, Gloria Roldan Urgoiti, Nadia Califaretti, Ahmet Alacacıoğlu, M. Gumus, Bülent Yalçın
Annals of Oncology. 2021741 CitationsOPEN ACCESS
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
Nancy U. Lin, Virginia F. Borges, Carey K. Anders, Rashmi K. Murthy, Elisavet Paplomata, Erika Hamilton, Sara A. Hurvitz, Sherene Loi, Alicia Okines, Vandana G. Abramson, Philippe L. Bédard, Mafalda Oliveira, Volkmar Müller, Amelia Zelnak, Michael P. DiGiovanna, Thomas Bachelot, A. Jo Chien, Ruth O’Regan, Andrew Wardley, Alison Conlin, David Cameron, Lisa A. Carey, Giuseppe Curigliano, Karen A. Gelmon, Sibylle Loibl, JoAl Mayor, Suzanne McGoldrick, Xuebei An, Eric P. Winer
Journal of Clinical Oncology. 2020556 CitationsOPEN ACCESS
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
Sara M. Tolaney, Andrew Wardley, Stefania Zambelli, John Hilton, Tiffany A. Troso-Sandoval, Francesco Ricci, Seock‐Ah Im, Sung‐Bae Kim, Stephen Johnston, Arlene Chan, Shom Goel, Kristen Catron, Sonya C. Chapman, Gregory L. Price, Zhengyu Yang, M. Corona Gainford, Fabrice André
The Lancet Oncology. 2020261 Citations

How much of the research on UK Research and Innovation is open access?

ScholarIQopen access share
60%OPEN ACCESS
Gold
0%
Green
20%
Hybrid
40%
Bronze
0%
Closed
40%

Related on ScholarIQ

470M+ articles · 14-day free trial